September 2021 - Page 3 of 3 - PsychedelicNewsWire (PNW)

MondaySep 13, 2021 12:35 pm

Biden Administration Streamlines Registration Processes for Research on Schedule I Substances

Last week, the White House Office of National Drug Control Policy recommended that a modification be made to the federal drug scheduling system in an effort to simplify the process of conducting studies on schedule I substances, which include cannabis and psychedelics like psilocybin. In a letter to Congressional leaders, the ONDCP stated that it wanted to encourage research on the substances by streamlining the registration process for researchers to access Schedule I drugs. This move is part of an extensive initiative to develop a strategy to decrease the supply of illicit fentanyl while diminishing barriers to scientific research on…

FridaySep 10, 2021 2:00 pm

DEA to Increase Psilocybin, Cannabis Production for Research Purposes

The United States Drug Enforcement Administration (“DEA”) has proposed an increase in the manufacture of cannabis, cannabis extract, psilocin and psilocybin for clinical trial and research purposes. In its most recent notice, the DEA stated that its objective was to assist in the development of new federally approved therapies. The DEA stated that it believes in supporting the regulated research of controlled substances classified under Schedule I of the Controlled Substances Act. The increase in the aggregate production quota reflects this support and will help meet the requirements for research needed for the production of new therapeutic medications. This isn’t…

ThursdaySep 09, 2021 1:45 pm

Study Finds That Ayahuasca May Enhance Self-Perception of Patients with Social Anxiety Disorder

A study that was recently published in the “Journal of Clinical Psychopharmacology” has found that ayahuasca could enhance the self-perception of individuals with social anxiety disorder. Ayahuasca is a psychedelic brew that has been used for hundreds of years by indigenous tribes in the Amazon. It contains monoamine oxidase inhibitors and DMT (dimethyltryptamine), another potent psychedelic. Preliminary studies have provided evidence suggesting that ayahuasca is psychologically beneficial to individuals who suffer from depression and anxiety. Rafael Guimarães dos Santos, the study’s author, states that social anxiety disorder is an under-diagnosed and prevalent disorder with limited treatment options. In the study,…

ThursdaySep 09, 2021 11:24 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Share Updates on Its PFN Program Pipeline at the Upcoming H.C Wainwright 23rd Annual Global Investor Conference

Tryp Therapeutics is set to present at the H.C Wainwright 23rd Annual Global Investor Conference scheduled for Sept. 13-15, 2021 Greg McKee, company chairman and CEO, will provide an overview of the business and its pipeline, including the Psilocybin-for-Neuropsychiatric Disorders (“PFN”) program Tryp’s presentation will be available on-demand from 7.00 a.m. EDT on Sept. 13 Through the PFN program, Tryp is focused on developing psychedelic compounds targeting diseases with high unmet medical needs, such as chronic pain conditions and eating disorders As a company at the forefront of the psychedelic renaissance, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has differentiated itself…

WednesdaySep 08, 2021 1:30 pm

Newfoundland Women Report Using Psychedelics Medicinally and Hope for Legalization

Researchers have found that psilocybin, which is the hallucinogenic compound found in so-called magic mushrooms, has shown potential in treating various mental conditions, including anxiety, major depressive disorder and addiction. A woman in Newfoundland who was diagnosed with severe PTSD revealed that psilocybin helped get her life back. The woman, whose identity remains withheld, stated that after her diagnosis, conventional medications and therapies helped for a while, but she eventually became resistant to them. When her sleep and anxiety became worse, she went to a psilocybin psychotherapy retreat in Jamaica where the substance is legal. She gave an account of…

WednesdaySep 08, 2021 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Completes Training for Upcoming Phase 2a Psychedelics Trial Targeting Eating Disorders

Tryp Therapeutics is a pharmaceutical company focused on establishing new drug candidates that will provide effective alternatives to established treatments for responding to medical conditions with largely unmet needs The company is preparing to launch a clinical trial with a 25mg synthetic psychedelic drug candidate, TRP-8802, to determine its efficacy and safety in treating select eating disorders in combination with psychotherapy Tryp recently announced that its educational partner, Fluence, has completed training of the psychotherapists who will be involved in administering the drug candidate to help establish minimal variability in the data outcomes and grant the patients the best possible…

TuesdaySep 07, 2021 2:00 pm

Not-for-Profit Organization Urges Health Canada to End Psilocybin Mushroom Prohibition

TheraPsil is urging Health Canada to end the five-decade prohibition against the possession of psilocybin mushrooms and the psychedelics these entheogenic fungi produce. The not-for-profit organization, which advocates for the therapeutic use of psilocybin, has spent months drawing up proposed legalization measures for these mushrooms based on the same regulations the federal government created for medical marijuana two decades ago. Spencer Hawkswell, CEO of the British, Columbia-based organization stated that TheraPsil had sent a proposal to Jennifer Saxe, who is the director general of Health Canada. In his statement, Hawkswell revealed that the 165-page document focused on managing every aspect…

FridaySep 03, 2021 2:00 pm

Bill to Legalize Psychedelics Possession in California Paused

A measure to legalize the possession of psychedelics such as ayahuasca and psilocybin in the state of California will not be advancing this session. The temporary halt to the bill occured after its sponsor decided that more time was needed to compile additional evidence for reform in order to solidify the bill’s chances of being passed. The bill, which had already been cleared in the Senate, will be made into a two-year legislation, which means it will not be advanced to the floor until 2022. The legislation was sponsored by Sen. Scott Wiener, who has spent a lot of time…

ThursdaySep 02, 2021 2:00 pm

Grand Rapids One Step Closer to Decriminalizing Entheogenic Plants, Fungi

The city of Grand Rapids, Michigan, may soon deprioritize the enforcement of laws against the use, growing and possession of entheogenic fungi and plants. Grand Rapids city commissioner Kurt Reppart stated that, while this wouldn’t decriminalize the psychedelics, it would allow individuals to gift, grow, use or possess psychedelics without facing any legal charges. Reppart is in favor of making psychedelics the lowest priority for the city’s law enforcement and believes that the move will not only acknowledge that these fungi and plants can not only be medicines for individuals using them to treat conditions such as anxiety, depression, addiction…

WednesdaySep 01, 2021 3:50 pm

Filmmaker Behind Netflix’s Psychedelics Documentary Is Working on Sequel

If you’re interested in psychedelics and have watched the “Adventures in Psychedelics” documentary on Netflix, you may soon be getting a sequel. The documentary’s writer, Donick Cary, recently revealed that a series or film — or both — is on the horizon, hinting at the possibility of a podcast as well. The “Adventures in Psychedelics” documentary first aired on Netflix in May 2020. However, it took more than a decade to make, with Mike Rosenstein, who was the producer, and Cary interviewing celebrities such as Anthony Bourdain, A$AP Rocky and Carrie Fisher about their experiences with psychedelics. This documentary, which…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Month: September 2021